



**University of Dundee**

## **Improvements with sublingual house dust mite immunotherapy in allergic rhinitis**

Lipworth, Brian

*Published in:*  
Journal of Allergy and Clinical Immunology

*DOI:*  
[10.1016/j.jaci.2016.03.033](https://doi.org/10.1016/j.jaci.2016.03.033)

*Publication date:*  
2016

*Licence:*  
CC BY-NC-ND

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*  
Lipworth, B. (2016). Improvements with sublingual house dust mite immunotherapy in allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 138(2), 634-635. <https://doi.org/10.1016/j.jaci.2016.03.033>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Manuscript Number: JACI-D-16-00269

Title: Improvements with sublingual house dust mite immunotherapy in allergic rhinitis.

Article Type: Correspondence re: Published Articles

Section/Category: Rhinitis, Sinusitis, and Upper Airway Disease

Keywords: immunotherapy; allergic rhinitis; house dust mite

Corresponding Author: Prof. Brian Lipworth, MD

Corresponding Author's Institution: University of Dundee

First Author: Brian Lipworth, MD

Order of Authors: Brian Lipworth, MD

Manuscript Region of Origin: UNITED KINGDOM

1

2

3 Improvements with sublingual house dust mite immunotherapy in allergic

4 rhinitis.

5

6

7 Corresponding Author:

8 Dr Brian Lipworth MD.

9 Scottish Centre for Respiratory Research

10 Ninewells Hospital and Medical School

11 University of Dundee, Scotland UK

12 [b.j.lipworth@dundee.ac.uk](mailto:b.j.lipworth@dundee.ac.uk)

13

14 Tel: 01382 383188 Fax: 01382 383259

15

16

17

18 Keywords: immunotherapy; allergic rhinitis; house dust mite

19

20

21 To the Editor,  
22 The results of Demoly et al<sup>1</sup> demonstrate promising effects of two doses of  
23 the house dust mite sublingual tablet in allergic rhinitis, with mean  
24 improvements in the primary outcome of the total combined rhinitis score  
25 (TCRS) exceeding the minimal clinically important difference (MCID) of 1.0.  
26 However on inspection of the 95% confidence intervals, it is evident that the  
27 lower bounds for improvements in TCRS were less than the MCID: reported  
28 changes from placebo were 0.45 (6.7% difference) and 0.49 (7.2% difference)  
29 for 6 and 12 SQ-HDM doses respectively, inferring that such responses were  
30 statistically significant but perhaps not so clinically meaningful<sup>2</sup>. Pointedly no  
31 clinically relevant improvements were observed in disease specific quality of  
32 life score. This in turn begs the question as to whether similar improvements  
33 would be seen with SQ-HDM in patients with persistent allergic rhinitis who  
34 were optimally treated with conventional pharmacotherapy.

35

36 Dr Brian Lipworth MD. Scottish Centre for Respiratory Research, Ninewells  
37 Hospital and Medical School, University of Dundee, Scotland UK

38 [b.j.lipworth@dundee.ac.uk](mailto:b.j.lipworth@dundee.ac.uk)

39

#### 40 References

41

- 42 1. Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-  
43 Tebbe J. Effective treatment of house dust mite-induced allergic rhinitis  
44 with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized,  
45 double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol  
46 2016; 137:444-51 e8.

47 2. Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ. The minimal  
48 clinically important difference in allergic rhinitis. *Clin Exp Allergy* 2010;  
49 40:242-50.

50